U.S. markets closed

Helix BioPharma Corp. (HBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.6300-0.0900 (-12.50%)
At close: 3:11PM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.7200
Open0.6200
Bid0.6200 x 0
Ask0.6400 x 0
Day's Range0.6100 - 0.6400
52 Week Range0.2500 - 1.1600
Volume12,201
Avg. Volume7,125
Market Cap88.914M
Beta (5Y Monthly)-0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.0540
Earnings DateJun 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • ACCESSWIRE

      Helix BioPharma Corp. Announces Appointment of Interim Chief Executive Officer

      RICHMOND HILL, ON / ACCESSWIRE / September 20, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company's Chairman of the Board, Prof.

    • ACCESSWIRE

      Helix BioPharma Corp. Announces Appointment of New Director

      RICHMOND HILL, ON / ACCESSWIRE / August 19, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr.

    • ACCESSWIRE

      Helix BioPharma Corp. Announces Changes to the Company's Board of Directors and Management

      RICHMOND HILL, ON / ACCESSWIRE / June 30, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Heman Chao has notified the Board of Directors of the Company of his intention to step down from the position of Chief Executive Officer ("CEO"), Chief Scientific Officer ("CSO") and member of the Board, effective September 1, 2021.